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Rationale: Primary ciliary dyskinesia (PCD) is characterized by recur-
rent airway infections and randomization of left–right body asym-
metry. To date, autosomal recessive mutations have only been iden-
tified in a small number of patients involving DNAI1 and DNAH5,
which encode outer dynein arm components.
Methods: We screened 109 white PCD families originating from
Europe and North America for presence of DNAH5 mutations by
haplotype analyses and/or sequencing.
Results: Haplotype analyses excluded linkage in 26 families. In 30
PCD families, we identified 33 novel (12 nonsense, 8 frameshift,
5 splicing, and 8 missense mutations) and two known DNAH5 muta-
tions. We observed clustering of mutations within five exons harbor-
ing 27 mutant alleles (52%) of the 52 detected mutant alleles.
Interestingly, 6 (32%) of 19 PCD families with DNAH5 mutations
from North America carry the novel founder mutation 10815delT.
Electron microscopic analyses in 22 patients with PCD with muta-
tions invariably detected outer dynein arm ciliary defects. High-
resolution immunofluorescence imaging of respiratory epithelial
cells from eight patients with DNAH5 mutations showed mislocaliza-
tion of mutant DNAH5 and accumulation at the microtubule or-
ganizing centers. Mutant DNAH5 was absent throughout the ciliary
axoneme in seven patients and remained detectable in the proximal
ciliary axoneme in one patient carrying compound heterozygous
splicing mutations at the 3-end (IVS75-2AT, IVS765GA). In a
preselected subpopulation with documented outer dynein arm de-
fects (n  47), DNAH5 mutations were identified in 53% of patients.
Conclusions: DNAH5 is frequently mutated in patients with PCD ex-
hibiting outer dynein arm defects and mutations cluster in five
exons.
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Primary ciliary dyskinesia (PCD; Mendelian Inheritance in Man
[MIM] 242650) is estimated to affect 1 in 10,000 to 20,000 individ-
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uals (1, 2). The complex PCD phenotype involving various organ
systems is explained by dysfunction of motile cilia and flagella,
respectively. Recurrent respiratory infections are caused by de-
fective mucociliary clearance due to immotile or dysmotile respi-
ratory cilia (3), resulting in chronic inflammation and bronchiec-
tasis. Dysfunction of monocilia at the embryonic node is
associated with randomization of left–right body asymmetry (4),
and half of the patients with PCD exhibit situs inversus. PCD
plus situs inversus is also referred to as Kartagener’s syndrome
(MIM 244400). Reduced fertility is often observed in male pa-
tients with PCD (5, 6). The inconclusive initial clinical presenta-
tion, particularly in children without situs inversus, often delays
diagnosis and may cause underestimation of the disease preva-
lence (7).
Respiratory cilia activity is generated by the action of dynein arm
complexes attached to the peripheral axonemal A-microtubules
(8–10). In PCD, various ultrastructural defects of the ciliary
axoneme have been identified. The most frequent abnormalities
comprise the absence of some or all outer dynein arms (ODAs)
(3); other defects include inner dynein arm (IDA) defects, micro-
tubule transpositions, and radial spoke defects (11).
PCD represents a heterogeneous group of genetic disorders.
In most cases, inheritance is autosomal recessive but other modes
of transmission have also been observed. DNAI1, the human
ortholog of the Chlamydomonas reinhardtii gene IC78, encodes
an intermediate chain of the ODA (12). To date, recessive
DNAI1 mutations have been detected in 6 of 47 studied PCD
families (13, 14), and approximately 50% of reported mutant
alleles comprise the splicing mutation 2193insT. Occasionally,
mutations in the RPGR gene located on the X chromosome,
which is responsible for 20% of all retinitis pigmentosa cases,
have been found in males with retinal degeneration and PCD
(15–17).
Applying a homozygosity mapping strategy, we previously
localized a PCD locus to chromosome 5p (18). Using a candidate
gene approach, we identified DNAH5, which is composed of 79
exons with one alternative first exon. DNAH5 encodes a heavy
chain of the ODA and is the human homolog of the dynein -
heavy chain of C. reinhardtii. Mutational analysis in 25 PCD
families in which haplotype analyses were consistent with linkage
to the DNAH5 locus detected recessive mutations in eight PCD
families (19). Here, we analyzed additional 109 PCD families with
various ultrastructural phenotypes for mutations in DNAH5. Con-
sidering the previous report of extensive genetic heterogeneity in
PCD (20), we unexpectedly found that DNAH5 mutations are
responsible for PCD in 28% of 109 analyzed PCD families.
Interestingly, half of PCD families with ODA defects harbored
DNAH5 mutations.
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METHODS
Patients
We collected blood samples from 134 affected PCD subjects and family
members belonging to 109 unrelated nuclear families. Ultrastructural
analyses revealed an ODA defect in 47 PCD families, whereas only
nine families exhibited an IDA defect (see the online supplement Figure
E2). Twenty-one families had parental consanguinity and diagnosis of
PCD was based on established criteria (1). Pedigrees of PCD families
were compatible with autosomal recessive inheritance. The geographic
origin was Europe (Germany, 46; United Kingdom, 10; Switzerland, 10;
Hungary, 8; Belgium, 1; The Netherlands, 2; Austria, 2; and Sweden, 1)
and North America, 29. To establish representative prevalence data,
we added the 25 PCD families analyzed in our previous study (19; see
Figures E3 and E4). In addition, 60 unrelated North American patients
were screened for the founder mutation 10815delT (32 had ODA de-
fects, 3 had IDA defects, 2 had central pair defects, 9 had normal dynein
arms). Informed consent was obtained using protocols approved by the
Institutional Ethics Review Board at the University of Freiburg and
collaborating institutions.
Haplotype Analysis
Haplotype analysis was performed in consanguineous families and fami-
lies with at least two affected individuals. Two highly polymorphic
intragenic microsatellite markers (MIC-DNAH5-1; MIC-DNAH5-3)
were tested as described previously (19). Using sequence information
of 60 single-nucleotide polymorphisms, we deduced haplotypes based
on genotypes of patients with homozygous mutations (F373, UNCB,
UNC47, UNC83) and the assumption of existing founder haplotypes
in patients with PCD originating from different families.
Mutational Analysis
Genomic DNA was isolated by standard methods directly from blood
samples or from lymphocyte cultures after Epstein-Barr virus transfor-
mation. Amplification of 80 genomic fragments comprising all 79 exons
and one alternative first exon of DNAH5 was performed as described
previously (19). Sequence data were evaluated using the Codoncode
software (CodonCode Corporation, Dedham, MA). To aid identifica-
tion of frequent polymorphisms, we sequenced samples from 10 healthy
control subjects. All identified mutations were confirmed by repeated
sequencing. We screened 140 control chromosomes originating from
healthy white individuals for the presence of missense and facultative
splicing mutations. Segregation analyses and screening of control
subjects were performed by restriction analysis, denaturing high-
performance liquid chromatography, or sequencing.
cDNA Analysis of the 1730GC Mutation
Total RNA was isolated by the TRIzol method or RNeasy Mini Kit
(Qiagen, Valencia, CA) from respiratory epithelial cells obtained by
nasal brush biopsies. First-strand cDNA synthesis was performed with
a SuperScriptII RNase kit (Invitrogen, Carlsbad, CA). As a control,
reverse transcriptase was omitted in a parallel reaction. To test whether
the splice donor site of exon 13 is mutated, a cDNA fragment corre-
sponding to exons 12–14 was amplified by polymerase chain reaction
(PCR; 52C annealing temperature) with primers spanning the junctions
of exons 11/12 and 14–15 (F: 5-TAA ATA CCA GGG CAT TGT
GG-3, R: 5-TTC TTC AAT TTG CCG AAG C-3), respectively.
Products were subjected to second-round amplification, cloned, and
subsequently sequenced (see Figure E5).
High-Speed Video Analysis of Cilia Beating
Ciliary beat frequency and beating pattern were assessed with the Sisson
Ammons Video Analysis (SAVA) system as described previously (21). We
examined nasal brush biopsies from five patients with PCD (OP40, OP51,
F718, OP54, OP31) in which novel DNAH5 mutations were detected.
Immunofluorescence Studies of Respiratory Epithelial Cells
Respiratory epithelial cells from patients OP9, OP31, OP40, OP51,
OP54, F718, UNC29, and UNC35 were obtained by transnasal brush
biopsy and processed for high-resolution immunofluorescence imaging
as described previously (21).
RESULTS
Mutational Analysis of DNAH5
We have previously shown that DNAH5 mutations cause PCD
and randomization of left–right asymmetry (19) (see Figure E3).
To determine the frequency of DNAH5 mutations in PCD, we
screened an additional large international cohort of 109 PCD
families (see Figure E2). In 26 PCD families, haplotype analyses
were not consistent with linkage to the DNAH5 locus, indicating
that DNAH5 mutations most likely are not responsible for the
disease phenotype in these families. Sequencing of all coding
exons, including the exon/intron boundaries in the remaining 83
families, revealed 33 novel DNAH5 mutations in patients with
PCD from 30 families or 34 affected patients (Figure 1). In
addition, the two previously reported frameshift mutations,
5563_5564insA and 8440-8447delGAACCAAA, were also iden-
tified in three and one patients, respectively (19). In only eight
families, one mutant allele was detected and the second mutant
allele remained unidentified (Table 1). The observed mutational
changes fell into two major groups: truncating (n  27; 77%)
and missense mutations (n  8; 23%). The 33 novel mutations
included 12 nonsense mutations, eight frameshift mutations,
three obligatory and two facultative splicing mutations
(1730GC; IVS765GA), as well as eight missense mutations.
The missense and facultative splicing mutations were absent
in 140 control chromosomes, and cosegregation of the mutations
with disease phenotypes was confirmed (Table 1). For facultative
splicing mutation (1730GC), aberrant splicing was confirmed
by reverse transcriptase–PCR analysis (see below). In the IV-
S765GA mutation, a conserved (80%) base pair is affected,
which predicts aberrant splicing. We considered the IV-
S765GA exchange to represent a mutation, because this
DNA variant was found twice in the PCD population but was
absent in the control population. In addition, cosegregation
within the two PCD families carrying the IVS765GA was
noted and deduced haplotype analysis (see below) was consistent
with a founder mutation.
The eight identified missense mutations affect amino acid
residues that have been evolutionarily conserved in the mouse
(AF466704) and/or C. reinhardtii (U15303) DNAH5 orthologs,
respectively. Two of these mutations are located within known
functional domains of DNAH5 (Figure 1). The mutation W3409S
is located in the microtubule binding site and S2264N resides in
the P2-loop domain of the protein.
We observed clustering of mutations within five exons harbor-
ing 27 mutant alleles (52%) of the 52 detected mutant alleles.
Clinical findings of PCD patients with DNAH5 mutations are
depicted in Table E2. No genotype–phenotype correlations have
been identified.
The 1730GC Mutation Results in Abnormal Splicing
In Patient UNC75 II1, we detected the heterozygous 1730GC
mutation, which affects an 80% conserved base pair of the splice
donor site of exon 13. To test whether this mutation indeed
affects splicing, we performed reverse transcriptase–PCR, which
showed two fragments corresponding to the wild-type (535 bp)
and a variant (449 bp) allele, consistent with heterozygosity (see
Figure E5). Cloning and subsequent sequencing of the PCR
products revealed that the 449-bp product fuses exon 12 out of
frame to exon 14 and therefore lacks exon 13, whereas the 535-bp
product coincides with the wild-type fragment. We conclude
that the mutant splice site cannot be recognized by the splicing
machinery, leading to skipping of exon 13, which predicts prema-
ture termination of translation because of out-of-frame fusion.
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Figure 1. Distribution of novel and published DNAH5 mutations. Top: schematic presentation of the genomic structure of DNAH5. Exons are
numbered and indicated by black boxes. Open boxes represent untranslated regions. ATG, start codons, TAA, stop codon. Intron sizes are not
drawn to scale. The positions of the intronic DNAH5 mutations are indicated by vertical lines. Bottom: schematic drawing of DNAH5. The P-loop
domains and the microtubule binding domain are shown. The positions of all identified exonic DNAH5 mutations are indicated by vertical lines.
Mutations that were detected in several unrelated families are marked by an asterisk ( 4 PCD families) and dagger (2 PCD families). Mutations
that were identified in our previous study are indicated by gray boxes (19). Novel mutations are depicted in red.
DNAH5 Mutations Cause PCD with ODA Defects
All patients carrying DNAH5 mutations that were studied by
transmission electron microscopy (n  22) exhibited ODA de-
fects. We have previously shown that at least two distinct ODA
complexes are found within human respiratory cilia and that
both contain DNAH5 and exhibit a distinct regional distribution
along the ciliary axoneme (21). In addition, we could demon-
strate in three patients carrying homozygous DNAH5 mutations
(5563_5564insA, 8440-8447delGAACCAAA, and IVS74-1GC)
that the mutated DNAH5 proteins were expressed but were
absent from the entire ciliary axoneme, and instead accumulated
at the ciliary base. This finding indicates that these DNAH5
mutations affect assembly of both ODA types. Here, we studied
an additional eight individuals with DNAH5 mutations for
DNAH5 localization in respiratory cells that were obtained by
nasal brushing biopsy. In all cases, we found expression of mutant
DNAH5. In seven individuals, we found a complete absence of
mutant DNAH5 from the ciliary axoneme and accumulation at
the ciliary base and within the cytoplasm (Figure 2B), as reported
previously (21). However, one patient (F718 II1) carrying com-
pound heterozygous mutations, which affect splicing at the
3-end of the gene (IVS 75 and 76), showed absence of DNAH5
only from the distal part of the ciliary axonemes (Figure 2C)
and remaining DNAH5 staining in the proximal part, indicating
that assembly of one type of ODA is at least partially preserved.
We previously observed this pattern of aberrant DNAH5 stain-
ing only in patients with DNAI1 mutations (21). Interestingly,
in nine individuals with isolated IDA defects, we did not find
DNAH5 mutations by sequence analysis. Thus, mutations of
DNAH5 encoding an ODA heavy chain most likely affect only
assembly of ODA complexes, but might not affect IDA assem-
bly. In the preselected subpopulation of patients with PCD with
documented ODA defects demonstrated by electron microscopy
and/or high-resolution immunofluorescence microscopy (n  47),
DNAH5 mutations were identified in 53% of patients.
We have previously shown that cilia with ODA defects are
immotile or only show flickering movements (21). We analyzed
patients with DNAH5 mutations by high-speed videomicroscopy
(n  5). Two of these patients (OP54, OP51) had completely
immotile cilia in all examined respiratory epithelial cells. In
three patients (OP31, OP40, F718), most respiratory cilia were
immotile; however, some cilia showed severely altered motility
with stiff movements and low amplitudes.
DNAH5 Founder Mutations
The mutations 10815delT, 5563_5564insA, 13458_13459insT,
IVS765GA, 8528TC, and 8440–8447delGAACCAAA
were found in seven, three, four, two, two, and one families,
respectively. Two of these mutations (5563_5564insA, 8440-
8447delGAACCAAA) were reported previously (19). To ad-
dress the question of whether these mutations were derived
from a common ancestor (founder) or occurred independently,
we took advantage of the high number of single-nucleotide poly-
morphisms present in the 250-kb DNAH5 locus to deduce the
haplotypes associated with the identified mutations. Because of
the large dataset, results representative (n  39) of 60 single-
nucleotide polymorphisms are depicted in Figure E1. The haplo-
type analysis was facilitated, because some affected individuals
carried homozygous mutations (5563_5564insA, 10815delT,
13458_13459insT). Analysis of the deduced haplotypes indicates
that the mutations 10815delT (UNCB, UNC47, UNC35, UNC74,
UNC29, UNC102, OP19), IVS765GA (UNC76, F718), and
8528TC (UNC35, UNC48) are founder mutations (see Figure
E1). Interestingly, for the mutations 5563_5564insA and
13458_13459insT, we could show that the mutational events most
likely occurred independently in some of the families, whereas
in other families, they are consistent with founder mutations (see
Figure E1). Consistent with these findings, the 5563_5564insA
mutation was identified in patients with PCD from Europe
(OP31 II1) and North America (UNC72 and UNC76) who share
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TABLE 1. DNAH5 MUTATIONS IN PRIMARY CILIARY DYSKINESIA
Family Patient Origin Exon DNA Change Protein Change ODA Defect Segregation
Homozygous
OP36 II1 Germany [36][36] [6037CT] [R2013X] n.a P  M
UNC47 II1 United States [63][63] [10815delT] [P3606HfsX23] EM n.d.  M
UNCB II1 United States [63][63] [10815delT] [P3606HfsX23] EM n.d.
UNC83 II1 United States [77][77] [13458_13459insT] [N4487fsX1] EM n.d.
Compound
UNC29 II1 United States [3][63] [232CT][10815delT] [R78X][P3606HfsX23] EM  IF P  M
UNC59 II1 United States [7][12] [832delG][1627CT] [A278RfsX27][Q543X] EM P  M
OP54 II1 Switzerland [17][48] [IVS172TC][7914_7915insA] splicing-mut.[R2639TfsX19] EM  IF P  M
UNC45 II1 United States [25][77] [3905delT][13458_13459insT] [L1302RfsX19][N4487fsX1] EM M  P
OP31 II1 Germany [27][34] [IVS271GA][5563_5564insA] splicing-mut.[I1855NfsX6] IF P  M
OP40 II1 Germany [32][77] [5147GT][13458_13459insT] [R1716L][N4487fsX1] IF M  n.d.
UNC72 II1 United States [33][34] [5281CT][5563_5564insA] [R1761X][I1855NfsX6] EM n.d.
UNC34 II1 United States [33][60] [5482CT][10226GC] [Q1828X][W3409S] EM P  M
OP19 III1 Germany [34][63] [5599_5600insC][10815delT] [L1867PfsX35][P3606HfsX23] n.a. P  M
UNC76 II1 United States [34][76] [5563_5564insA][IVS765GA] [I1855NfsX6]splicing-mut. EM n.d.
OP51 II1,II2 Switzerland [41][76] [6791GA][13194_13197delCAGA] [S2264N][D4398EfsX16] EM  IF M  n.d.
UNC32 II1 United States [43][45] [7039GA][7502GC] [E2347K][R2501P] EM n.d.
F668 II1 Germany [49][49] [8029CT][8167CT] [R2677X][Q2723X] n.a. P  M
UNC31 II1,II2 United States [50][77] [8404CT][13426CT] [Q2802X][R4476X] EM M  n.d
UNC35 II1 United States [51][63] [8528TC][10815delT] [F2843S][P3606HfsX23] EM  IF M  n.d.
UNC102 II1,II2,II3 United States [63][77] [10815delT][13486CT] [P3606HfsX23][R4496X] EM P  M
UNC74 II1 United States [63][77] [10815delT][13458_13459insT] [P3606HfsX23][N4487fsX1] EM M  n.d.
F718 II1 Germany [76][76] [IVS75–2AT][IVS765GA] splicing-mut.splicing-mut. IF n.d.  M
Heterozygous
UNC81 II1 United States [3]n.d. [252TG)n.d. [Y84X]n.d. EM n.d.
UNCK II1 United States [11]n.d. [1426_1427delTT]n.d. [F476SfsX26]n.d. EM n.d.
UNC75 II1 United States [13]n.d. [1730GC]n.d. splicing-mut.n.d. EM P
OP9 II1 Hungary [50]n.d. [8440_8447delGAACCAAA]n.d. [E2814fsX1]n.d. EM  IF P
CH-6475 II1 Switzerland [50]n.d. [8314CT]n.d. [R2772X]n.d. n.a. n.d.
UNC48 II1 United States [51]n.d. [8528TC]n.d. [F2843S]n.d. EM M
OP3 II1 Germany [67]n.d. [11528CT]n.d. [S3843L]n.d. n.a. n.d.
UNC87 II1 United States [73]n.d. [12614GT]n.d. [G4205V]n.d. EM M
Definition of abbreviations: EM  electron microscopy; IF  immunofluorescence; M  maternal; mut.  mutation; n.a.  not available; n.d.  not determined;
ODA  outer dynein arm; P  paternal.
the same haplotype. In contrast, their haplotype differs from the
haplotype of an Arab patient with PCD (F373), who carries the
5563_5564insA mutation reported previously (19). Similarly, we
found three North American patients with PCD (UNC45,
UNC74, and UNC83) with identical deduced haplotypes carrying
the 13458_13459insT mutation and one patient with PCD from
Europe (OP40 II1) with a different deduced haplotype. The
10815delT founder mutation was found in six United States’
PCD families and one European PCD family. To confirm that
this mutation is especially prevalent within the United States’
PCD population, we screened 60 patients in the United States
and identified in four PCD families the 10815delT founder muta-
tion. In two of these families, ultrastructural analysis was avail-
able and showed ODA defects.
Prevalence of DNAH5 Mutations
By adding 25 previously analyzed PCD families (Germany
[n  10], United Kingdom [n  7], Belgium [n  2], and North
America [n  6]) to the 109 analyzed PCD families, we calculated
the frequency of mutations in all 134 apparently unrelated PCD
families that have been thus far analyzed for DNAH5 mutational
status (19) (see Figures E2–E4). In these 134 PCD families from
Europe and North America, 38 families (51 affected individuals)
were detected carrying DNAH5 mutations, which represents an
overall frequency of 28%. All patients with PCD with DNAH5
mutations were white. In the subpopulation of patients with
PCD with documented ODA defects demonstrated by electron
microscopy and/or high-resolution immunofluorescence micros-
copy (n  65), DNAH5 mutations were identified in 49% of
patients. To date, a total of 66 mutant alleles are known. Muta-
tions seem to cluster within the five exons 34, 50, 63, 76, and 77,
which harbor 31 (47%) mutant alleles (see Table E1 and Figure
E4). In 20 (53%) PCD families carrying DNAH5 mutations, at
least one mutation within these five exons was detected.
DISCUSSION
The most frequent ultrastructural defects in PCD affect the
composition of dynein arms, which are responsible for cilia and
sperm tail movement (11, 22–24). Linkage studies suggest exten-
sive genetic heterogeneity in PCD (20). So far, only two genes,
DNAI1 and DNAH5, have been clearly linked to autosomal
recessive forms of PCD (12, 19). DNAH11 mutations possibly
also cause PCD (25). All three genes encode for components
of ODA complexes.
This study determined the frequency, distribution, and the
phenotype associated with DNAH5 mutations. DNAH5 is a large
gene comprising 79 exons and one alternative first exon and
encodes a heavy chain of the ODA. We have recently shown
that recessive DNAH5 mutations are responsible for PCD char-
acterized by ODA defects (19). The murine ortholog Mdnah5
(alias Dnahc5) is expressed in the node during early embryonic
development, in the respiratory tract and in testes, which is
consistent with disease manifestations in PCD (19, 26). In this
current study, we report analysis of an additional PCD cohort
comprising 109 PCD families and detected 33 distinct novel
mutations and two mutations reported previously (Table 1).
Mutations were scattered along the entire coding region (Figure 1).
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Figure 2. Mis-localization of
mutant DNAH5 in respiratory
epithelial cells from patients
with primary ciliary dyskinesia
carrying DNAH5 mutations.
Confocal immunofluorescence
analysis of human respiratory
epithelial cells with anti-
DNAH5 antibodies (red) and
with antibodies against axo-
neme-specific acetylated 	-tu-
bulin (green) as control (21).
Nuclei were stained with
Hoechst 33342 (blue). (A) In re-
spiratory epithelial cells from
healthy probands, DNAH5 lo-
calizes along the entire length
of the axonemes and at the mi-
crotubule organizing centers.
(B) In respiratory epithelial cells
from patient OP40 II1, carrying
the compound heterozygous
DNAH5 mutations R1716L and
4487NfsX1, mutant DNAH5 is
expressed and correctly tar-
geted to the ciliary base where
it accumulates. In contrast to
healthy control subjects, we
observed complete absence of
mutant DNAH5 from the ciliary
axonemes. (C) In Patient F718
II1, who carries compound heterozygous DNAH5 mutations affecting splicing at the 3-end of the gene, mutant DNAH5 is absent from the distal
part of the ciliary axonemes but is still detectable within the proximal part.
Most of the identified mutations were nonsense mutations, but
frameshift, splicing, and missense mutations were also found.
The most common DNAH5 mutations clustered within only five
exons, 34, 50, 63, 76, and 77, which harbor DNAH5 mutations
in 53% of a total of 134 analyzed PCD families (see Table E1
and Figure E4). The increased frequency of mutant alleles in
only 5 of the 80 known coding exons of DNAH5 might help to
develop a fast and cost-effective genetic assay for genetic diagno-
sis in the future. Six mutations (5563_5564insA, 10815delT,
13458_13459insT, 8440-8447delGAACCAAA, 8528TC, and
IVS765GA) were identified in more than one unrelated PCD
family. Three of the identified DNAH5 mutations (5563_
5564insA, 10815delT, and 13458_13459insT) were found in four,
seven, and four families, respectively. Based on the large number
of single-nucleotide polymorphisms within the DNAH5 locus, we
were able to analyze whether these sequence variants occurred
because of independent mutational processes or are related to
ancestral founders. These analyses indicate that 10815delT,
8528TC, and IVS765GA are founder mutations (Figure
E1). For two of the other mutations (5563_5564insA and 13458_
13459insT), we found a more complex situation, where, in some
PCD families, the mutations probably occurred independent
from each other and, in others, deduced haplotypes suggest a
common ancestor (Figure E1). Importantly, we could demon-
strate that the 10815delT mutation is especially prevalent in the
white PCD population in the United States. We confirmed that
genetic screening for this mutation is notably useful in United
States’ PCD families and identified additional four PCD families
in a cohort of 60 analyzed PCD families in the United States.
Previously, we studied the axonemal ultrastructure in several
patients with PCD carrying DNAH5 mutations. All patients
exhibited deficiency of ODAs (19, 26), which is consistent with
DNAH5 constituting one component of the large multimeric
ODA complexes. Here, evaluation of electron microscopic data
from a large cohort of patients (n  109) with DNAH5 mutations
(n  22) confirmed ultrastructural ODA defects in all cases,
including patients carrying missense mutations. Interestingly, we
did not find DNAH5 mutations in patients without ODA defects
by electron microscopy. Importantly, patients with PCD with
isolated IDA defects did not harbor DNAH5 mutations. On the
basis of these observations, we conclude that DNAH5 mutations
regularly disturb the correct assembly of ODA complexes.
To gain more insight into the molecular pathology of PCD
caused by DNAH5 mutations, we analyzed respiratory cells ob-
tained by nasal brushing biopsy from eight patients with PCD
with recessive DNAH5 mutations. We have previously shown
that human respiratory cilia contain at least two ODA types,
which differ in their content of dynein heavy chains and which
show differences concerning their regional distribution along
the ciliary axoneme: type 1 (DNAH9-negative and DNAH5-
positive; proximal ciliary axoneme) and type 2 (DNAH9- and
DNAH5-positive; distal ciliary axoneme) (21). In the study pre-
sented here, we show by high-resolution immunofluorescence
imaging that, regardless of the mutational background, mutant
DNAH5 proteins are expressed in respiratory epithelial cells
from patients with PCD, but are not appropriately localized along
the axonemal shaft (Figure 2). Consistent with the available ultra-
structural data exhibiting ODA deficiency, we identified in all eight
analyzed patients with PCD with DNAH5 mutations mislocaliza-
tion of mutant DNAH5 with accumulation at the microtubule
organizing centers. Because all mutations result in mutant
DNAH5 with preservation of the N-terminal third of the protein,
we assume that this region contains a domain responsible for
correct targeting of DNAH5 to the microtubule organizing
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centers. In all but one patient with PCD with DNAH5 mutations,
we found complete absence of mutant DNAH5 from the respira-
tory ciliary axonemes, as reported previously in three patients
with PCD with DNAH5 mutations (21). In these cases, mutations
affect assembly of both ODA complexes that contain DNAH5
(Figure 2B). In contrast, in one patient (F718), we found that
mutant DNAH5 was absent from the distal ciliary axoneme, but
was preserved within the proximal ciliary axoneme (Figure 2C).
This staining pattern clearly demonstrates that, in this patient,
mutant DNAH5 can be correctly targeted to the site of proxi-
mally located ODA complexes. F718 carries compound hetero-
zygous mutations located at the 3-end of DNAH5 (IVS 75 and
76), which both predict aberrant splicing. This indicates that the
C-terminal region of DNAH5 is important for assembly of ODA
type 2. Such a staining pattern was so far not observed in patients
with DNAH5 mutations but only in patients carrying DNAI1
mutations (21).
The primary goal of current therapy for patients with PCD
is prevention of progressive lung damage (27). The strict treat-
ment of infections of the upper and lower airways, appropriate
therapy regarding chronic otitis media, and consequent physical
therapy may result in increased quality of life and retardation
of chronic lung failure. However, therapeutic options that correct
cilia dysmotility to restore mucociliary clearance are currently
not available. Recently, it has been shown that aminoglycoside
antibiotics are able to suppress the usage of premature termina-
tion codons by permitting translation to continue to the normal
termination of translation (28, 29). Clinical studies using phar-
maco-gene therapy in patients with cystic fibrosis carrying pre-
mature nonsense mutations in the CFTR gene provided compel-
ling evidence that the aminoglycoside gentamicin can suppress
stop mutations in the CFTR gene and restore CFTR function
(30–32). Here, we found DNAH5 nonsense mutations in a high
proportion of patients with PCD. This opens the possibility to
use pharmaco-gene therapy to correct the primary defect in
these patients with PCD. In future in vitro studies, we will address
this question by treating primary human respiratory epithelial
cells from patients with PCD carrying nonsense DNAH5 muta-
tions with aminoglycosides. Possibly, this will lead to the devel-
opment of novel therapeutic strategies in PCD.
A recent work studying a large cohort of patients with PCD
for the presence of DNAI1 mutations shows that mutations in
this gene can be identified in 13% of PCD families with ODA
defects (M.A. Zariwala and coworkers, submitted for publica-
tion). To date, 134 PCD families have been screened for muta-
tions in DNAH5 and recessive mutations were identified in 49%
of PCD families with ODA defects (see Figure E4). Thus, al-
though PCD represents a genetically heterogeneous disorder,
DNAH5 dysfunction appears to be a major cause of PCD with
ODA defects.
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